New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
08:01 EDTAMGNXencor initiates Phase 1b/2a trial of XmAb5871
Xencor announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb5871 in patients with moderate to severe rheumatoid arthritis.  XmAb5871 is the first in a new class of therapeutic antibodies targeting the CD32b pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion. The trial initiation triggered a milestone payment of an undisclosed amount to Xencor from Amgen. XmAb5871 is a humanized and Fc engineered monoclonal antibody that uses a uniquely selective dual-targeting mechanism for B cell inhibition by co-engaging CD19 and CD32b. Amgen and Xencor entered into an option and co-development agreement for XmAb5871 in January 2011. Amgen has the option to an exclusive worldwide license following the completion of a pre-defined Phase 2 study. Xencor will lead all clinical development until that time and is eligible for early development milestone payments.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
08:21 EDTAMGNAmgen submitts MAA to EMA for evolocumab
Subscribe for More Information
08:20 EDTAMGNAmgen submits application to EMA for talimogene laherparepvec
Subscribe for More Information
08:01 EDTAMGNAmgen price target raised to $153 from $140 at Leerink
Subscribe for More Information
August 31, 2014
12:50 EDTAMGNEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 28, 2014
09:18 EDTAMGNAmgen anounces Evolocumab YUKAWA-2 study meets co-primary endpoints
Subscribe for More Information
09:04 EDTAMGNAmgen submits evolocumab BLA to FDA
Subscribe for More Information
August 27, 2014
09:20 EDTAMGNFDA grants Amgen priority review designation for ivabradine
Amgen announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure. Ivabradine is an oral drug that inhibits the If current in the sinoatrial node, the body's cardiac pacemaker. The New Drug Application is based on global clinical trial data from the Phase 3 SHIFT, or Systolic Heart failure treatment with the If inhibitor ivabradine Trial), study. The SHIFT study compared ivabradine to placebo on top of standard-of-care therapies, including beta-blockers, in more than 6,500 patients in sinus rhythm with reduced left ventricular function and heart rate greater than 70 beats per minute.
August 26, 2014
11:21 EDTAMGNAmgen added to short term buy list at Deutsche Bank
Subscribe for More Information
August 25, 2014
16:17 EDTAMGNWestern Digital CFO Leyden to retire, Olivier Leonetti to succeed
Western Digital (WDC) announced that CFO Tim Leyden is retiring. He is being succeeded by Olivier Leonetti, who has served as vice president, finance at Amgen (AMGN) from 2011. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8.
August 19, 2014
05:11 EDTAMGNGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use